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Confocal microscopy of idarubicin localisation in sensitive and multidrug-
resistant bladder cancer cell lines
PM Duffy, MC Hayes, A Cooper and CJ Smart
Department of Urology, Southampton University Hospitals NHS Trust, Southampton
Summary Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to
conventional anthracyclines. Confocal microscopy demonstrates predominantly cytoplasmic idarubicin
accumulation. This distribution is unaltered by resistance status or the resistance reversing agent verapamil.
Our results contrast with studies on conventional anthracycines and suggest that nuclear accumulation may
not be a prerequisite for anthracycline cytotoxicity.
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Anthracyclines are widely used chemotherapy agents.
Thought to act primarily as DNA intercalators (Plosker
and Faulds, 1993) they are effective against a wide range of
tumours. However, their clinical utility is limited by
multidrug resistance (MDR). Cells displaying MDR become
resistant both to anthracyclines and to other agents such as
the vinca alkaloids, actinomycin D and the epipodophyllo-
toxins (Plosker and Faulds, 1993; Berman and McBride,
1992). Typically, MDR cells take up less drug than sensitive
equivalents. This phenomenon may result from plasma
membrane drug efflux pumps such as P-glycoprotein (P-gp,
Moscow et al., 1993), although the mechanism remains
controversial (Roepe, 1992). Multidrug resistance-associated
protein (MRP, Zaman et al., 1994) and lung resistance-
related protein (LRP, Scheffer et al., 1995) have also been
recently described as mediating MDR.
Because anthracyclines fluoresce, it is possible to visualise
their intracellular distribution. Viable sensitive and MDR
cells appear to sequester conventional anthracyclines
differently (Coley et al., 1993; Gervasoni et al., 1991; Duffy
et al., 1996). Sensitive cells display nuclear drug fluorescence,
whereas MDR cells show predominantly cytoplasmic
fluorescence. Interestingly, MDR-reversing agents such as
verapamil cause the intracellular distribution of these drugs
in MDR cells to revert to the sensitive pattern (Coley et al.,
1993).
Idarubicin is a relatively new anthracycline. Of greater
lipophilicity than earlier derivatives, it appears more effective
than its predecessors, especially in the treatment of tumours
resistant to these agents (Berman et al., 1992). We have
studied the distribution of idarubicin fluorescence in sensitive
and P-glycoprotein-expressing MDR sublines of the MGHU-
1 bladder cancer cell line (Floyd et al., 1990).
Materials and methods
Sensitive and MDR clones of the MGHU-1 bladder cancer
cell line were obtained from the Institute of Urology, UCL.
The resistant subline was produced by continuous exposure
to doxorubicin and has been shown to express P-gp (Floyd et
al., 1990). Studies using JSBI and MRPl have demonstrated
high expression of P-gp in the MDR subline, but no
overexpression of MRP (MC Loizidou, personal commu-
nication). The cells were cultured using Dulbecco's modified
Eagle medium (DMEM), 10% fetal calf serum (FCS) and
antibiotics at 37°C in humidified 5% carbon dioxide in air.
Subculture was achieved using trypsin-EDTA. Anthracycline
(Pharmacia) stock solutions, (1 mg ml-' Hanks' balanced salt
solution) were frozen at -20°C.
Confocal microscopy
Sensitive and resistant MGH-U1 cells were seeded into
60 mm Petri dishes and reincubated overnight, allowing the
cells to adhere. Two hours before microscopy, the medium
was changed to HEPES-buffered DMEM with 10 pg ml-' of
anthracycline with or without verapamil 25 ,ug ml-'. Cell
viability after confocal microscopy was confirmed by trypan
blue exclusion (0.02% w/v).
Confocal microscopy was performed using the Leica TCS
4D system, the fibre optic laser emitting at 488 nm. Cells
were imaged in the incubation medium using a x 50 water
immersion lens. Consistent images were obtained on three
separate occasions using identical incubation conditions.
Pinhole and electronic variables were kept constant through-
out.
MTT cytotoxicity studies
Cytotoxicity experiments were performed using the MTT
assay (Freshney, 1994). Cells were seeded in 96-well
microtitre plates and exposed to drug at 37°C for 1 h on
the following day. Five days later, the plates were incubated
with MTT (0.2 mg ml-', 250 pl per well) for 4 h, treated with
dimethyl sulphoxide (DMSO) and viable biomass determined
on a Dynatech MR 5000 plate reader.
Spectrofluorimetry studies
Spectrofluorimetry experiments were carried out at drug
concentrations of 10 pg ml-' using a Perkins-Elmer LS-5B
scanning spectrofluorimeter.
Results
Confocal microscopy uses dual-pinhole optics and raster
pattern scanning to produce high definition, fluorescence-
based images, enabling intact, viable cells to be visualised
as a series of slices. Figure la shows the typical,
predominantly nuclear epirubicin distribution in sensitive
MGHU-1 cells. In contrast, Figure lb shows punctate
cytoplasmic and perinuclear epirubicin distribution in the
MDR MGHU-1 cells. These results correspond with
published results using other conventional anthracyclines
such as daunorubicin or doxorubicin (Coley et al., 1993;
Gervasoni et al., 1991).
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Figure 2a shows idarubicin distribution in sensitive
MGHU-1 cells. Unlike other anthracyclines in sensitive
cells, idarubicin fluorescence appears predominantly peri-
nuclear and cytoplasmic. In some cells an area of intense
cytoplasmic drug fluorescence is visible, possibly representing
the Golgi apparatus. There is relatively little nuclear drug
fluorescence.
Figure 2b demonstrates idarubicin distribution in MGHU-
1-resistant cells. Although this specimen shows reduced
idarubicin fluorescence, drug distribution remains similar to
the sensitive cells.
Addition of 25 pg ml-' of verapamil to the idarubicin
solution increases drug fluorescence in the resistant cells, but
appears to make no difference to the distribution of
idarubicin fluorescence in either sensitive (Figure 3a) or
resistant (Figure 3b) MGHU-1 cells. MTT cytotoxicity
studies confirm the P-gp-expressing subline to 100-fold more
resistant to idarubicin (Figure 4). Addition of 25 pg ml-1 of
verapamil reduces this resistance by a factor of ten.
DNA-mediated fluorescence quenching demonstrates that
idarubicin fluoresces more strongly in free solution than the
related anthracyclines epirubicin and doxorubicin (Figure 5).
Between DNA concentrations of 0.02-0.06 mg ml-', idar-
ubicin demonstrates a greater degree of fluorescence
quenching. At greater concentrations, however, the pattern
of quenching appears the same.
Discussion
These results contrast with studies performed on conven-
tional anthracyclines by ourselves and others. Using doxo-
dauno- and epirubicin, nuclear drug fluorescence has been
associated with sensitivity, and cytoplasmic fluorescence with
resistance (Coley et al., 1993; Gervasoni et al., 1991).
Additionally, the morpholinyl-substituted analogue of dox-
orubicin (MR-DOX) is known to retain activity in MDR
cells, and high levels of nuclear MR-DOX fluorescence in
MDR cell lines have been demonstrated (Coley et al., 1993).
Although the precise antineoplastic mechanism of action
of anthracyclines is still debated, current evidence suggests
that these agents intercalate DNA. They may stabilise the
topoisomerase-DNA cleavable complex or inhibit DNA
helicase activity, thereby reducing replication and transcrip-
b
Figure 1 Confocal micrograph of (a) sensitive and (b) resistant
MGH-Ul cells incubated for 2h in 10pgml- epirubicin, x 50
water immersion objective. Grey-scale image proportional to
fluorescence intensity.
Figure 2 Confocal micrograph of (a) sensitive and (b) resistant
MGH-U1 cells incubated for 2h in gmlF- idarubicin, x 50
water immersion objective. Grey-scale image proportional to
fluorescence intensity.
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Figure 4 MTT cytotoxicity assay of sensitivity to idarubicin of
parental and MDR MGH-Ul cells, with and without verapamil
25pgml-'. Mean viable biomass +s.e.m. x 2.576. (-U-),
sensitive; (-E-), sensitive and verapamil; (-*-), resistant;
(-A-), resistant and verapamil.
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Figure 3 Confocal micrograph of (a) sensitive and (b) resistant
MGH-Ul cells incubated for 2h in 10 gml-l idarubicin and
25 jugml- 1 verapamil, x 50 water immersion objective. Grey-scale
image proportional to fluorescence intensity.
tion (Plosker and Faulds, 1993). As idarubicin is widely
regarded as more effective against MDR cells than older
anthracyclines (Berman and McBride, 1992), it is curious that
nuclear idarubicin fluorescence should appear diminished in
both sensitive and MDR cells.
These anomalous findings do not correlate with signifi-
cantly altered fluorescence quenching. Lankelma et al. (1991)
demonstrated 95% fluorescence quenching with daunorubicin
and calf thymus DNA. Our own work with doxorubicin,
epirubicin and idarubicin shows only minor differences in
fluorescence quenching between idarubicin and the two
conventional anthracyclines and does not explain the
striking differences in nuclear fluorescence observed with
the confocal microscope.
These results are also relevant to our understanding of the
phenomenon of MDR. Verapamil dramatically increases the
nuclear uptake and cytotoxicity of conventional anthracy-
clines in MDR cells (Coley et al., 1993; Michieli et al., 1994).
Figure 5 Anthracycline -calf thymus DNA fluorescence
quenching. Excitation wavelength =488 nm. (- - -), epirubicin
(lOpgml-'); (--), doxorubicin (10 gml-P); ( ), idarubicin
(lOpgml-').
Our own MTT cytotoxicity studies confirm that addition of
verapamil to idarubicin preparations increases idarubicin
cytotoxicity in the MDR MGH-Ul cell line (Figure 5).
However, confocal microscopy demonstrates that the
addition of verapamil to idarubicin does not restore nuclear
drug fluorescence in either the parental or MDR cell line,
suggesting that substantial nuclear drug presence may not be
a prerequisite for effective anthracycline cytotoxicity in
sensitive cells, or for overcoming MDR.
Considerable work remains to be done, both on the
putative mechanism of action of anthracyclines, and on the
fundamentals of MDR and MDR reversal. We believe that
our results are relevant to the continuing study of these
mechanisms and that it is premature to assume that nuclear
drug fluorescence necessarily correlates with cytotoxicity.
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